How Are Viruses Diagnosed? Methods and Test Results

Viruses are diagnosed through a handful of core approaches: molecular tests that detect viral genetic material, antigen tests that detect viral proteins, antibody tests that reveal past infection, and, less commonly, cell culture methods that grow the virus in a lab. Which test a clinician orders depends on what question needs answering, whether the patient is currently infected, has been infected before, or is shedding enough virus to be contagious. Each method has trade-offs in speed, sensitivity, and cost, and understanding those trade-offs helps make sense of what your test result actually means.

Molecular Tests and How They Work

Molecular tests look for a virus’s genetic material, either DNA or RNA, in a sample. The most widely used is RT-PCR (reverse transcription polymerase chain reaction), which became a household term during the COVID-19 pandemic. The test works by copying tiny fragments of viral RNA over and over in cycles until there’s enough material to detect. A key output is the cycle threshold, or Ct value: the number of copying cycles needed before the virus becomes detectable. A lower Ct value means more virus was present in the original sample, while a higher Ct value means less virus was there to start with.¹

RT-PCR is extremely sensitive. It can pick up as few as one to a hundred viral copies per milliliter of sample, depending on the assay.² That sensitivity is a double-edged sword: the test can remain positive for weeks after someone is no longer contagious, because it detects fragments of dead virus alongside live virus. This is why a positive PCR result alone doesn’t always mean you’re infectious, a point that caused enormous confusion during the pandemic.

A faster molecular alternative is RT-LAMP (loop-mediated isothermal amplification). Unlike PCR, which requires a machine that cycles through different temperatures, LAMP runs at a single temperature and can produce a visible color change you read with the naked eye. One benchmarking study found that an RT-LAMP assay detected SARS-CoV-2 with 100% sensitivity and about 96% specificity for samples containing more than 100 viral copies, delivering results within 30 minutes.³ However, LAMP tests lose sensitivity at low viral loads. In one head-to-head comparison, the sensitivity of a commercial RT-LAMP assay dropped from about 93% for samples with Ct values below 30 down to roughly 17% for samples with Ct values above 35.⁴ So LAMP works well when viral load is moderate or high, but can miss early or late-stage infections where the virus is scarce.

Rapid Antigen Tests

Rapid antigen tests, the kind many people used at home during the pandemic, detect specific proteins on the surface of the virus rather than its genetic material. They use lateral flow technology: you add your sample to a strip, the liquid migrates along the strip, and if viral proteins are present, they bind to antibodies that produce a visible line. The whole process takes about 15 minutes and requires no lab equipment.

The trade-off is sensitivity. Antigen tests generally need between 100,000 and 1,000,000 viral copies per milliliter to produce a positive result, compared with the one-to-hundred copies that molecular tests can detect.² A large evaluation of 22 different rapid lateral flow tests for SARS-CoV-2 found that their sensitivity compared with molecular testing ranged from about 30% to 80%, varying by brand and by which viral variant was circulating.⁵ That wide range means a negative antigen test doesn’t rule out infection as reliably as a negative PCR test does.

This gap between antigen and molecular tests isn’t unique to COVID. Even in the 1990s, researchers evaluating RSV detection found that enzyme immunoassays caught roughly 72–94% of positive cases compared with other methods, depending on the assay and specimen type.⁶ For influenza A, a dot-blot enzyme immunoassay showed about 85% sensitivity against shell-vial culture, while a direct immunofluorescence method managed only about 59%.⁷ The lesson across decades of virology is consistent: antigen-based methods trade sensitivity for speed and simplicity.

Where rapid antigen tests shine is in identifying people who are most likely to be contagious. Because they require a higher viral load to turn positive, a positive antigen test is a strong signal that you’re shedding a lot of virus. CDC surveillance data found that for SARS-CoV-2, antigen test sensitivity was highest on days when the person had a fever (about 77% compared with PCR), while on days with no symptoms the sensitivity fell to just 18%.⁸ Clinicians sometimes describe antigen tests as better at detecting infectiousness than infection.

When a False Positive Isn’t a Real Infection

One of the stranger findings from the pandemic was that rapid antigen tests could produce false-positive results when used incorrectly. Researchers demonstrated that applying a sample directly to the test strip without the kit’s buffer solution caused false-positive lines that looked identical to genuine positives.⁹ The explanation turned out to be simple chemistry: the buffer maintains the right pH and salt concentration so that the antibodies on the test strip only bind the target viral protein. Without it, the antibodies clump together nonspecifically and produce a line. This is why squeezing fruit juice, soda, or other liquids directly onto a test strip, as some viral videos demonstrated, could trigger a “positive” result that had nothing to do with a virus.

The practical takeaway is that the accuracy of any rapid test depends heavily on following the instructions. The buffer isn’t a decorative step; it’s a critical part of the assay chemistry. Similarly, test performance degrades if a kit has been stored at extreme temperatures, has expired, or if the specimen was collected poorly. These user-dependent variables contribute to the wide range in real-world sensitivity that studies report.

Antibody Tests and What They Tell You

Antibody (serological) tests don’t detect the virus itself. They detect your immune system’s response to it. When you’re infected with a virus, your body produces antibodies, typically IgM antibodies first, followed by longer-lasting IgG antibodies. A positive antibody test generally means you’ve been infected at some point, or that you’ve been vaccinated, but it doesn’t tell you much about whether you’re currently sick.

The timing matters. For SARS-CoV-2, studies found that IgG antibodies typically became detectable around 10 to 13 days after symptoms began, with substantial individual variation.¹⁰ In a Japanese cohort, IgG crossed the detectable threshold around days 9–10 and stayed elevated, while IgM peaked at about day 18 and then declined, and in most patients IgG actually appeared before IgM, which surprised some researchers since the textbook pattern is the opposite.¹¹ This means antibody tests are largely useless during the first week of illness; a negative antibody result in that window says nothing about whether you’re infected.

Antibody tests are more useful for population-level surveillance, figuring out what percentage of a community has been exposed to a virus, and for confirming immunity after vaccination. But they have important accuracy limits. For measles, two commercial IgG ELISAs agreed with the gold-standard neutralization test about 92% of the time, but roughly 10% of sera with low antibody levels came back falsely negative.¹² For mumps, the discordance was even more striking: about 17% of samples came back positive on a standard ELISA but negative on a neutralization assay, suggesting the ELISA detected binding antibodies that didn’t actually neutralize the virus.¹³ In other words, a positive antibody test doesn’t always mean you’re protected.

Why the Sample You Collect Matters

You can have the best test in the world, but if the sample is poor, the result will be unreliable. For respiratory viruses, the nasopharyngeal swab, the long swab inserted deep into the nose until it reaches the back of the throat, has traditionally been the standard because it collects from where many respiratory viruses replicate. Comparison studies confirm that nasopharyngeal swabs tend to yield the highest viral concentrations.¹⁴

But the picture is more nuanced than “nasopharyngeal is always best.” One study found that early morning saliva actually detected SARS-CoV-2 at a higher rate than nasopharyngeal swabs (about 93% versus 53%), with lower Ct values in the saliva samples, suggesting more virus was present.¹⁵ A broader comparison across multiple respiratory viruses found that saliva and nasopharyngeal swabs had similar overall detection rates (about 76–78%), though some viruses were found more often in one sample type than the other: adenovirus turned up more in saliva, while influenza A and rhinovirus were more common in nasopharyngeal specimens.¹⁶

Even within the same sample type, technique matters. The same comparison study found that the vigor of nasal swabbing made a measurable difference: swabs collected with ten rubs yielded significantly lower Ct values (more virus) than swabs collected with five rubs.¹⁴ A half-hearted swipe around the nostril is genuinely less likely to catch a virus that’s sitting deeper in the nasal passages. If you’re doing a home test, the uncomfortable part is doing it right.

Timing and the Window of Detection

When you test can be just as important as how you test. Every virus has a characteristic shedding curve: viral load rises after exposure, peaks somewhere around the time symptoms are worst, and gradually declines. For SARS-CoV-2, CDC surveillance data showed that the peak percentage of positive PCR results occurred about three days after symptom onset (83%), while positive antigen results also peaked at day three but at a lower rate (59%). Positive viral cultures, the best marker of live, potentially transmissible virus, peaked a day earlier, at day two.⁸

Other viruses follow different patterns. A systematic review of mpox found that viral load peaked in skin lesions within about six days of symptom onset, while in other specimen types like anorectal and pharyngeal swabs the trends unfolded over about seven to eight days. The review also established Ct cutoff values beyond which viral cultures were unlikely to succeed, offering a rough guide for how long patients remain infectious by specimen type: about 19 days for anorectal samples, 14 for saliva, and 14 for urethral samples.¹⁷

The practical message: testing too early (before the virus has replicated enough to detect) or too late (after the immune system has largely cleared it) can produce a negative result even though you were infected. If you test negative on a rapid antigen test within the first day or two of symptoms, retesting 48 hours later makes sense because viral load may not have risen enough yet.

Multiplex Panels That Test for Several Viruses at Once

Coughing, fever, sore throat, and fatigue are symptoms shared by influenza, SARS-CoV-2, RSV, and a dozen other respiratory pathogens. A single-target test can tell you whether you have one specific virus, but multiplex panels test for many at the same time. In a clinical validation of one multiplex PCR assay applied to over a thousand samples, about half came back positive for at least one pathogen, and the most common findings were influenza A (about 21%), influenza B (about 12%), and Mycoplasma pneumoniae (about 9%). Roughly 5% of positive samples harbored two pathogens simultaneously, including co-infections involving SARS-CoV-2.¹⁸

Co-infections are clinically relevant because treatment varies by pathogen: influenza may warrant antivirals, while bacterial co-infections may need antibiotics. A single-virus test that comes back negative can leave both patient and clinician guessing, whereas a multiplex panel can catch what a targeted test misses. Research into multiplexed LAMP-based point-of-care devices is working toward the same goal outside the lab, with one prototype simultaneously detecting SARS-CoV-2, influenza, and RSV from saliva samples with strong agreement to RT-PCR results.¹⁹

Metagenomic Sequencing for Mystery Infections

Sometimes a patient is clearly sick with something, but every standard test comes back negative. Metagenomic next-generation sequencing (mNGS) takes a different approach: instead of looking for a single target, it sequences all the genetic material in a sample and computationally sifts through it to identify any pathogen present. This unbiased approach can detect rare, novel, or hard-to-culture viruses that targeted tests would never find.²⁰ It has increasingly been used for diagnostically challenging cases, such as travelers returning with unexplained febrile illness.²¹

Metagenomic sequencing isn’t a routine first-line test. It’s expensive, requires specialized bioinformatics, and takes longer than targeted molecular tests. But its ability to discover things no one was specifically looking for makes it invaluable for surveillance and outbreak investigations. It’s essentially the “catch-all” of viral diagnostics, the test you turn to when you’ve run out of hypotheses.

Cell Culture and the “Gold Standard” Label

Growing a virus in cultured cells is the oldest and in some respects the most definitive way to confirm its presence. A positive culture proves the virus is not just present but viable, able to infect living cells, something no molecular test can distinguish. Cell culture has historically been called the gold standard for virus isolation, though modern molecular methods are more sensitive and far faster.²²

In practice, culture is mainly used in research and reference laboratories rather than for routine patient care. Growing a virus can take days to weeks, and not all viruses grow well in standard cell lines. A comparison of RSV detection methods from the early 1990s illustrates the point: conventional culture detected only about 40% of positive cases, while faster techniques like direct immunofluorescence and enzyme immunoassay detected 83–87%.²³ Culture’s strength is confirming viability and providing live virus for further study, not speed or sensitivity.

CRISPR-Based and Smartphone Diagnostics

The gene-editing tool CRISPR has been adapted into diagnostic platforms. Systems like SHERLOCK and DETECTR use CRISPR enzymes to recognize specific viral sequences and then trigger a detectable signal, often a color change or a fluorescent glow. These platforms can be designed for point-of-care use, potentially combining the sensitivity of molecular detection with the simplicity of a rapid test.²⁴ They’ve been paired with various readout methods and are still largely in development, though several received emergency authorization during the pandemic.²⁵

Smartphones are also being integrated into diagnostic workflows. Researchers have built microfluidic chips that perform RT-LAMP amplification on a small card, then use a phone camera to read the color change and display a result. One such platform simultaneously detected Zika, dengue, and chikungunya from whole blood on the same chip.²⁶ Another used nanomaterial-enhanced colorimetric detection on a phone-readable platform to identify avian influenza at concentrations low enough to be clinically relevant, aimed specifically at low-resource settings.²⁷ These tools are still largely experimental, but they point toward a future where molecular-grade viral diagnostics could be done almost anywhere with minimal infrastructure.

Testing Wastewater to Track Whole Communities

Not all virus detection happens with individual patient samples. Wastewater-based epidemiology, or testing the sewage of a city or neighborhood, has become a powerful public health surveillance tool. Because infected people shed viral RNA in their stool and urine, sampling wastewater can reveal the presence and trajectory of a virus in a community before clinical testing catches up. This approach offers real-time insight into community health and is particularly valuable for monitoring vulnerable populations who may not seek individual testing.²⁸

During the COVID-19 pandemic, wastewater surveillance programs were rapidly deployed around the world. These programs complemented individual diagnostic testing by detecting surges in viral circulation days before hospital admissions spiked, giving public health officials earlier warning.²⁹ The technique has since been extended to track other pathogens including poliovirus, influenza, and RSV. It can’t tell you whether any specific individual is infected, but it can signal that a virus is spreading before anyone shows up at a clinic.

Access, Cost, and the Global Picture

The most accurate test in the world doesn’t help if you can’t get it. Lab-based RT-PCR remains the diagnostic backbone in wealthy countries, but it requires trained technicians, stable electricity, cold-chain reagent storage, and expensive thermal cycling equipment. A systematic review of COVID-19 diagnostic economics noted that most cost-effectiveness research came from high-income countries, and the findings couldn’t be straightforwardly applied to low- and middle-income settings where infrastructure and pricing differ dramatically.³⁰

The problem is well illustrated by hepatitis C. The standard diagnostic pathway requires a two-step process: first an antibody screening test, then a confirmatory RNA test to see if the infection is still active. In many low- and middle-income countries, the infrastructure for RNA testing is centralized in urban facilities, meaning rural patients who test antibody-positive often never come back for the second test. Cost is another barrier: many patients simply can’t afford the diagnostic workup.³¹ This is one of the reasons rapid, low-cost, point-of-care tests remain so important even when more sensitive lab tests exist. A slightly less sensitive test that you can actually access is more useful than a perfect test in a lab 200 kilometers away.

Emergency Use Authorization and What It Means for Test Reliability

During a public health emergency, tests often reach the market through emergency use authorization rather than the full regulatory approval process. In the United States, the FDA’s EUA pathway allows diagnostic tests to be deployed based on more limited evidence than would normally be required, provided they meet a reasonable belief standard of effectiveness. During COVID-19, the vast majority of molecular tests used in clinical settings operated under EUA rather than full FDA clearance.³² This was necessary to get testing scaled up quickly, but it also meant performance characteristics varied more widely across different commercial assays. Some EUA tests performed as well as or better than pre-pandemic gold standards; others had notable gaps. Laboratories were expected to perform verification studies on each assay they adopted, but the rigor of those verifications varied.

For the average person, the takeaway is that “FDA authorized” during an emergency isn’t quite the same bar as “FDA approved.” It doesn’t mean a test is bad. Many EUA tests proved excellent. But it does mean that performance can vary between brands and platforms more than you might expect, which partly explains why some home antigen tests worked noticeably better than others during the pandemic.